# Eculizumab (Soliris) in Covid-19 Infected Patients

> **NCT04288713** · — · AVAILABLE · sponsor: **Hudson Medical**

## Conditions studied

- Coronavirus

## Interventions

- **DRUG:** Eculizumab

## Key facts

- **NCT ID:** NCT04288713
- **Lead sponsor:** Hudson Medical
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2020-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04288713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04288713, "Eculizumab (Soliris) in Covid-19 Infected Patients". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04288713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*